For it to become more feasible, powerful, reliable tools can fuel scientific discoveries and drive exponential progress to refine genetic analysis for developing better treatment regimens. A study by Grand View Research reveals that the global single-cell analysis market size was valued at 3.28 billion in 2021 and is expected to expand at a compound annual growth rate CAGR) of 18.5 per cent from 2022 to 2030. Aware of the burgoing growth of single-cell-analysis market, Dr Ben Hindson, President Co-Founder of 10x Genomics explains how innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more areas using innovative diagnosis and therapy techniques.
What are the drivers and trends shaping the single-cell-analysis market? How do you Identify growth segments for investment and expansion?
More and more, we see that single cell methods are becoming the standard for a growing fraction of life science research, an essential element of many new grant applications and are increasingly becoming a requirement for publication.
Our goal at 10x Genomics is to make single cell analysis accessible to every biology lab in the world to make it the standard for most biological research.
Since the initial launch of our Single Cell Gene Expression solution, we have released many new capabilities and versions of our products focused on expanding the range of applications on the platform, including immune-profiling, epigenetics, proteins and multi-omics.
We have expanded the fundamental capabilities of the platform, highlighted by the release of the Chromium X instrument, which has made it possible for people to run up to 1 million cell experiments routinely.
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.
Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.
Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis
US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LCMS) analysis.
Singapore designs novel gene therapy offering hope for epilepsy patients
Researchers from the Yong Loo Lin School of Medicine, National University of Singapore are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.
Spider venom heart drug moves to clinical trials in Australia
A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).
India develops portable ultrasound scanner for sports injury diagnosis
A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.
Integris appoints medtech veteran Probir Das as new CEO
Integris Healthcare, a global diversified medical technology company, has announced the appointment of Probir Das as Chief Executive Officer (CEO). He will join effective November 2024 and will be based in New Delhi.
Clarity Pharma promotes Michelle Parker to CEO
Australia-based Clarity Pharmaceuticals has announced the appointment of Michelle Parker as Chief Executive Officer (CEO), effective from October 11, 2024.
Dr Makoto Sugita steps in as President of Nxera Pharma Japan
Nxera Pharma Co., formerly known as Sosei Group or Sosei Heptares, has announced the appointment of Dr Makoto Sugita, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.
